These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 25142313)

  • 1. Therapeutic uses of anti-interleukin-6 receptor antibody.
    Kang S; Tanaka T; Kishimoto T
    Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biology and medical implications of interleukin-6.
    Tanaka T; Kishimoto T
    Cancer Immunol Res; 2014 Apr; 2(4):288-94. PubMed ID: 24764575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role and therapeutic targeting of IL-6 in rheumatoid arthritis.
    Narazaki M; Tanaka T; Kishimoto T
    Expert Rev Clin Immunol; 2017 Jun; 13(6):535-551. PubMed ID: 28494214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
    Tanaka T; Narazaki M; Ogata A; Kishimoto T
    Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapeutic implication of IL-6 blockade.
    Tanaka T; Kishimoto T
    Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [IL-6 blockade therapy for inflammatory diseases: current perspectives and future directions].
    Tanaka T
    Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):433-42. PubMed ID: 27118330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of the interleukin-6 receptor.
    Tanaka T; Narazaki M; Kishimoto T
    Annu Rev Pharmacol Toxicol; 2012; 52():199-219. PubMed ID: 21910626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin (IL-6) Immunotherapy.
    Tanaka T; Narazaki M; Kishimoto T
    Cold Spring Harb Perspect Biol; 2018 Aug; 10(8):. PubMed ID: 28778870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.
    Tanaka T; Narazaki M; Kishimoto T
    FEBS Lett; 2011 Dec; 585(23):3699-709. PubMed ID: 21419125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
    Nakahara H; Nishimoto N
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):373-81. PubMed ID: 17214583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.
    Murakami M; Nishimoto N
    Curr Opin Rheumatol; 2011 May; 23(3):273-7. PubMed ID: 21427577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of blocking IL-6 receptor.
    Mima T; Nishimoto N
    Curr Opin Rheumatol; 2009 May; 21(3):224-30. PubMed ID: 19365268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 6: from bench to bedside.
    Nishimoto N; Kishimoto T
    Nat Clin Pract Rheumatol; 2006 Nov; 2(11):619-26. PubMed ID: 17075601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan.
    Nishimoto N
    Clin Rev Allergy Immunol; 2005 Jun; 28(3):221-30. PubMed ID: 16129906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 as a key player in systemic inflammation and joint destruction.
    Fonseca JE; Santos MJ; Canhão H; Choy E
    Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
    Nishimoto N
    Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.
    Tanaka T; Kishimoto T
    Int J Biol Sci; 2012; 8(9):1227-36. PubMed ID: 23136551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab (Actemra).
    Sheppard M; Laskou F; Stapleton PP; Hadavi S; Dasgupta B
    Hum Vaccin Immunother; 2017 Sep; 13(9):1972-1988. PubMed ID: 28841363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
    Paul-Pletzer K
    Drugs Today (Barc); 2006 Sep; 42(9):559-76. PubMed ID: 17028666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights.
    Hashizume M; Tan SL; Takano J; Ohsawa K; Hasada I; Hanasaki A; Ito I; Mihara M; Nishida K
    Int Rev Immunol; 2015 May; 34(3):265-79. PubMed ID: 25099958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.